These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15828852)

  • 41. Gastroesophageal reflux and histamine2 antagonists.
    Bell SG
    Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
    [No Abstract]   [Full Text] [Related]  

  • 42. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry.
    Zhong L; Eisenhandler R; Yeh KC
    J Mass Spectrom; 2001 Jul; 36(7):736-41. PubMed ID: 11473396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Famotidine-associated delirium. A series of six cases.
    Catalano G; Catalano MC; Alberts VA
    Psychosomatics; 1996; 37(4):349-55. PubMed ID: 8701013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design.
    Walson PD; Halvorsen M; Edge J; Casavant MJ; Kelley MT
    Clin Ther; 2013 Feb; 35(2):135-40. PubMed ID: 23351277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.
    Manitpisitkul P; Shalayda K; Todd M; Wang SS; Ness S; Ford L
    Epilepsia; 2013 Jan; 54(1):156-64. PubMed ID: 23157581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-dose pharmacokinetics of nizatidine (Axid) in children.
    Abdel-Rahman SM; Johnson FK; Manowitz N; Holmes GB; Kearns GL
    J Clin Pharmacol; 2002 Oct; 42(10):1089-96. PubMed ID: 12362922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
    Panasci L; Stinson SF; Melnychuk D; Sandor V; Miller WH; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
    J Clin Oncol; 2003 Jan; 21(2):232-40. PubMed ID: 12525514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of bumetanide in critically ill infants.
    Sullivan JE; Witte MK; Yamashita TS; Myers CM; Blumer JL
    Clin Pharmacol Ther; 1996 Oct; 60(4):405-13. PubMed ID: 8873688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired bioavailability of famotidine given concurrently with a potent antacid.
    Barzaghi N; Gatti G; Crema F; Perucca E
    J Clin Pharmacol; 1989 Jul; 29(7):670-2. PubMed ID: 2569486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical pharmacokinetics of famotidine.
    Echizen H; Ishizaki T
    Clin Pharmacokinet; 1991 Sep; 21(3):178-94. PubMed ID: 1764869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and dynamics of famotidine in patients with renal failure.
    Gladziwa U; Klotz U; Krishna DR; Schmitt H; Glöckner WM; Mann H
    Br J Clin Pharmacol; 1988 Sep; 26(3):315-21. PubMed ID: 2902874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical study on the influence of a fixed-dose combination of famotidine with calcium carbonate and magnesium hydroxide on the bioavailability of famotidine.
    Zhai Q; Fu J; Huang X; Xu B; Yuan YZ; Jiang T; Rong ZX; Chen HZ
    Arzneimittelforschung; 2008; 58(11):581-4. PubMed ID: 19137909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
    Gladziwa U; Wagner S; Dakshinamurty KV; el Desoky E; Dreuw B; Klotz U
    Eur J Clin Pharmacol; 1993; 44(4):357-60. PubMed ID: 8513846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.